BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of gentiopicroside derivatives as potential antiviral inhibitors. 2017

Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an 710069, China; Sorbonne Universités, UPMC Univ Paris 06, Institut Parisien de Chimie Moléculaire, CNRS UMR 8232, 4 place Jussieu, 75005 Paris, France.

Based on classical drug design theory, a novel series of gentiopicroside derivatives was designed and synthesized. All synthesized compounds were then biologically evaluated for their inhibition of influenza virus and anti-HCV activity in vitro. Some of the gentiopicroside derivatives, such as 11a, 13d and 16 showed interesting anti-influenza virus activity with IC50 at 39.5 μM, 45.2 μM and 44.0 μM, respectively. However, no significant anti-HCV activity was found for all of gentiopicroside derivatives. The preliminary results indicate that modification of the sugar moiety on gentiopicroside was helpful for enhancing the anti-influenza activities. Our works demonstrate the importance of secoiridoid natural products as new leads in the development of potential antiviral inhibitors.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D009975 Orthomyxoviridae A family of RNA viruses causing INFLUENZA and other respiratory diseases. Orthomyxoviridae includes INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INFLUENZAVIRUS D; ISAVIRUS; and THOGOTOVIRUS. Influenza Viruses,Myxoviruses,Orthomyxoviruses,Influenza Virus,Myxovirus,Orthomyxovirus
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D057888 Iridoid Glucosides A subclass of iridoid compounds that include a glucoside moiety, usually found at the C-1 position. Iridoid Glucoside,Iridoidglucoside,Secoiridoid Glucoside,Iridoidglucosides,Secoiridoid Glucosides,Glucoside, Iridoid,Glucoside, Secoiridoid,Glucosides, Iridoid,Glucosides, Secoiridoid

Related Publications

Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, synthesis and biological evaluation of coumarin derivatives as potential BRD4 inhibitors.
November 2022, Bioorganic chemistry,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, synthesis, and biological evaluation of chrysin derivatives as potential FabH inhibitors.
January 2017, Chemical biology & drug design,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, Synthesis, and Biological Evaluation of Benzimidazole Derivatives as Potential Lassa Virus Inhibitors.
February 2023, Molecules (Basel, Switzerland),
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
October 2015, Bioorganic & medicinal chemistry letters,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Novel flavonol derivatives containing benzoxazole as potential antiviral agents: design, synthesis, and biological evaluation.
January 2024, Molecular diversity,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Phenanthridine Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Design, Synthesis and Biological Evaluation.
January 2022, Current computer-aided drug design,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, Synthesis, and Biological Evaluation of 2-Mercaptobenzoxazole Derivatives as Potential Multi-Kinase Inhibitors.
January 2023, Pharmaceuticals (Basel, Switzerland),
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors.
August 2020, Bioorganic & medicinal chemistry letters,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
December 2018, Bioorganic & medicinal chemistry,
Shaoping Wu, and Lili Yang, and Wenji Sun, and Longlong Si, and Sulong Xiao, and Qi Wang, and Luc Dechoux, and Serge Thorimbert, and Matthieu Sollogoub, and Demin Zhou, and Yongmin Zhang
Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors.
March 2017, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!